Detailed Abstract
[Poster Presentation 6 - Biliary & Pancreas (Others(ERAS, Education etc.))]
[BP PP 6-S4] “Obesity Paradox” As a New Insight from Long-term Survivor in Pancreatic Cancer Patients
Boram LEE 1, Ho-Seong HAN 1, Yoo-Seok YOON 1, Jai Young CHO 1, Hae Won LEE 1
1 Department of Surgery, Seoul National University Bundang Hospital, REPUBLIC OF KOREA
Background : The role of obesity in oncological outcomes for cancer patients remains ambiguous. Intriguingly, some studies have indicated that obese patients showed improved survival compared, a phenomenon known as the “obesity paradox”. Nevertheless, no studies have specially examined the impact of obesity on patients with pancreatic cancer (PC). Hence, this study aims to elucidate the presence of the obesity paradox in PC.
Methods : A total of 404 patients who underwent pancreatectomy for PC from 2004 to 2020 were included. Patients were categorized based on the WHO classification (body mass index (BMI) exceeding 25kg/m2 considered overweight); the non-obese group (NOG, n=313) and the obese group (OG, n=91). Survival curves were then compared. Furthermore, to assess the impact of BMI, we conducted a subgroup analysis differentiating between early stage (Stage I-II) and advanced stage (Stage III-V) patients.
Results : In the overall comparison, the 5-year overall survival (OS) was significantly higher in the OG group compared to the NOG group (38.9% vs. 11.4%, P=0.028). However, these was no difference in 5-year recurrence free survival between group (OG vs. NOG group, 27.7% vs 30.1%, P=0.743). In subgroup analysis, in the early stage, the 5-year overall survival was significantly higher in the OG group than NOG group (P=0.007). However, no differences were observed in the advanced stage.
Conclusions : This study reveals that the presence of the “obesity paradox” in PC. Obese patients demonstrated significantly better 5-year OS, particularly in early-stage disease. These findings underscore the complex relationship between obesity and PC outcomes, emphasizing the importance of personalized care approaches.
Methods : A total of 404 patients who underwent pancreatectomy for PC from 2004 to 2020 were included. Patients were categorized based on the WHO classification (body mass index (BMI) exceeding 25kg/m2 considered overweight); the non-obese group (NOG, n=313) and the obese group (OG, n=91). Survival curves were then compared. Furthermore, to assess the impact of BMI, we conducted a subgroup analysis differentiating between early stage (Stage I-II) and advanced stage (Stage III-V) patients.
Results : In the overall comparison, the 5-year overall survival (OS) was significantly higher in the OG group compared to the NOG group (38.9% vs. 11.4%, P=0.028). However, these was no difference in 5-year recurrence free survival between group (OG vs. NOG group, 27.7% vs 30.1%, P=0.743). In subgroup analysis, in the early stage, the 5-year overall survival was significantly higher in the OG group than NOG group (P=0.007). However, no differences were observed in the advanced stage.
Conclusions : This study reveals that the presence of the “obesity paradox” in PC. Obese patients demonstrated significantly better 5-year OS, particularly in early-stage disease. These findings underscore the complex relationship between obesity and PC outcomes, emphasizing the importance of personalized care approaches.
SESSION
Poster Presentation 6
Zone G 3/21/2024 2:50 PM - 3:30 PM